Global Business Reports


Catherine Howe, Neha Premjee

India Pharmaceuticals 2017

November 28, 2017

India’s pharmaceutical industry, ranked third worldwide in terms of volume, is the largest supplier of generic drugs globally and a proponent of high-quality affordable medicines. The industry has posted double-digit growth over the last few years, rising to US$36.7 billion and projected to grow to US$40 billion by 2020. However, as price erosion continues to impact the market and competition increases, many of India’s pharmaceutical companies will be hard-pressed to continue pushing products into the market at ever-more affordable prices. A number of policies under discussion, outlined in the Draft Pharmaceutical Policy 2017, seek to address the challenges faced by Indian pharmaceutical companies. Implementation and open dialogue between government and industry will be key in ensuring its success.


BMGI India offers expertise is improving efficiencies in strategy, innovation, problem solving and business transformation.
Cogent Glass, recently acquired by SGD Pharma, is a manufacturer of Type I moulded and tubular glass vials for the pharmaceutical industry.
Signet is India’s largest excipient company with extensive activities extending to Bangladesh and the Middle East.
Telangana State contains one of India’s most important life science clusters and its Government explains to GBR its plans to maintain the State’s rapid industrial growth.


"The real danger is that some companies may still want to trade off the old business model of six years ago."